<DOC>
	<DOCNO>NCT02078557</DOCNO>
	<brief_summary>This study assess multiple dos MK-8892 administer participant pulmonary hypertension `` proportion '' ( PHOOP ) heart failure reduce leave ventricular ejection fraction ( rEF ) . It hypothesize generally safe well tolerated multiple dos MK-8892 achieve true reduction baseline pulmonary vascular resistance ( PVR ) great 12 % .</brief_summary>
	<brief_title>A Multiple Dose Titration Study MK-8892 Participants With Pulmonary Hypertension Left Heart Disease ( MK-8892-007 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Pulmonary hypertension ( proportion , PHOOP ) heart failure reduce leave ventricular ejection fraction ( PHOOP/rEF ) If female , pregnant breastfeeding . Females reproductive potential must agree agree use ( and/or partner use ) two ( 2 ) acceptable method birth control throughout study 2 week last dose study drug administer Body mass index ( BMI ) &lt; =35 kg/m^2 &lt; =18 kg/m^2 Has World Health Organization ( WHO ) Group 2 pulmonary hypertension ( PAH ) Stable heart failure optimal medical therapy hospitalization congestion due heart failure within previous 3 month Primary pulmonary arterial hypertension venoocclusive disease ( WHO Group 1 ) , pulmonary hypertension secondary cause ( WHO Groups 3 5 ) include limited autoimmune disease , connective tissue disease , Eisenmenger syndrome Currently treatment anticipates use nitrate , phosphodiesterase type 5 ( PDE5 ) inhibitor , medication know induce inhibit cytochrome P450 3A4 ( CYP3A4 ) metabolism , transition therapy &gt; =7 day prior dose completion study Symptoms coronary artery disease require therapy nitrate , within past 3 month Severe aortic mitral stenosis , severe aortic , mitral , tricuspid insufficiency . Significant carotid artery disease Restrictive , infiltrative ( e.g. , amyloidosis ) hypertrophic cardiomyopathy Mentally legally institutionalize incapacitated , significant emotional problem time pre study ( screen ) visit expect conduct study history clinically significant psychiatric disorder last 5 year . Subjects situational depression may enrol study discretion investigator . History stroke , chronic seizure , major neurological disorder History clinically significant endocrine ( include diabetes mellitus ) , gastrointestinal , hematological , hepatic ( include chronic Hepatitis C ) , immunological ( include chronic human immunodeficiency virus [ HIV ] ) , respiratory , genitourinary abnormality disease . Participants history childhood asthma may enrol study discretion investigator . Participants control hypertension allow enrol . Unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy ( St. John 's Wort [ hypericum perforatum ] ) begin approximately 2 week ( 5 halflives ) prior administration dose study drug , throughout study ( include washout interval treatment period ) , post study visit . There may certain medication permit . Consumes excessive amount alcohol , define great 5 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit [ 25 mL/1 ounce ] ) per day Major surgery donate blood within 8 week prior pre study ( screen ) visit Participated another investigational study within 4 week prior pre study ( screen ) visit History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Uses illicit drug history drug ( include alcohol ) abuse within past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>